R. Scott Struthers

Dr. Struthers is the Founder and CEO of Crinetics Pharmaceuticals Inc. Prior to Crinetics, he was Senior Director and Head, Endocrinology, and Metabolism at Neurocrine Biosciences. There he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, which has demonstrated safety and efficacy in over 40 clinical trials totaling more than 3,000 patients. Prior to Neurocrine, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets and led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery and structural biology. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange (sdentrepreneurs.org) and currently serves as its President. He is an author of more than 75 scientific publications in the fields of computational and medicinal chemistry, endocrinology, receptor biology, and clinical pharmacology. He holds a Ph.D. in physiology and pharmacology from the University of California, San Diego.